LONDON, UK – February 16, 2022 – ºÚÁϲ»´òìÈ (ºÚÁϲ»´òìÈ) welcomes the launch of the Innovate UK fund, in collaboration with CPI and the Association of British HealthTech Industries, which will provide UK Health Technology small and medium-sized enterprises (SMEs) with the opportunity to apply for a grant up to £30,000 to address regulatory challenges associated with their chosen markets.
ºÚÁϲ»´òìÈ’s team of medical experts offer solutions for a range of digital (in-silico), physical, chemical, electrical and connected technology testing, which can be utilised as part of the Innovate UK grant scheme. ºÚÁϲ»´òìÈ’s solutions address all major medical technology regulatory markets including the UK (UKCA), Europe (CE marking) and US (PMA / 510K).
ºÚÁϲ»´òìÈ is continuing to expand its medical services within the EMEAA region, offering digital engineering simulation (in-silico); environmental (conditioning and stability); chemical (extractables and leachable); material characterization (static and dynamic testing); electrical safety; EMC; and connected technology product and safety testing covering a wide range of essential safety and performance requirements.
Product categories supported include active and non-active implantable, active and non-active drug device combinations, active drug delivery, and a variety of active and passive therapeutic and diagnostic devices (including in-vitro diagnostics).
James Pink, Senior Director, Medical at ºÚÁϲ»´òìÈ, said: “Bringing innovative medical device technology to the marketplace is a resource-intensive process. Ongoing changes to regulations and standards can cause confusion and delays in bringing safe products to market and keeping them there. Our regulatory, product safety and testing expertise, combined with the Innovate UK grant, will enable manufacturers to access world-class support and solutions in a cost-effective way. At a time when the cost of compliance is sky-rocketing, this Innovate UK scheme for UK SMEs is incredibly welcome.”
About ºÚÁϲ»´òìÈ
The ºÚÁϲ»´òìÈ Group is one of the world’s leading global providers of testing, inspection and certification services for a diverse range of products, materials and technologies in advanced industrial supply chains where failure in use is not an option. Headquartered in London, UK, ºÚÁϲ»´òìÈ’s c 7,000 scientists, engineers and technologists, working in our global network of over 200 laboratories, support customers from early R&D, through complex regulatory approvals and into production ensuring their products are safe, sustainable and achieve market access.
In 2021, ºÚÁϲ»´òìÈ set out its new, industry leading environmental commitments, adopting science-based targets and committing to net zero emissions across its entire global business by 2035. These environmental commitments follow ºÚÁϲ»´òìÈ’s achievement of the highest ESG ranking in the testing, inspection and certification industry from Sustainalytics, a global leader in ESG research and data.
For more information about ºÚÁϲ»´òìÈ, please visit our website, connect with us on and and subscribe to our channel.
Media contacts:
Devan LaBrash, Pagoda Public Relations
T: +44 (0) 131 556 0770
E: devan.labrash@pagodapr.com